Application of a 1-benzhydryl-4-methylpiperazine compound in the preparation of antidepressant drugs

Abstract

The disclosure discloses the application of a 1-benzhydryl-4-methylpiperazine compound in the preparation of antidepressant drugs, which belongs to the field of medicine. The compound 1-benzhydryl-4-((1-benzene 1H-1,2,3-triazol-4-yl)methyl)piperazine can significantly improve the depression-like behavior in chronic unpredictable stress model mice. Mechanistic studies have shown that the compound 1‑benzhydryl‑4‑((1‑phenyl‑1H‑1,2,3‑triazol‑4‑yl)methyl)piperazine can improve the effects of chronic unpredictable stress Induced intestinal flora disturbance in mice; and has a protective effect on the integrity of the intestinal barrier and blood-brain barrier.

Description

technical field

[0001] The disclosure belongs to the technical field of medicine, and specifically relates to a compound 1-benzhydryl-4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazine in Application in the preparation of antidepressant drugs. Background technique

[0002] Depression is a common mental illness, mainly manifested as low mood, loss of interest, pessimism, slow thinking, lack of initiative, self-blame, poor diet and sleep, etc. In severe cases, suicidal thoughts and behaviors may appear. Serious physical and mental harm. With social and economic development, the pace of life continues to accelerate, and the incidence of depression increases year by year. In 2019, the number of depressed patients worldwide exceeded 350 million. It is estimated that by 2030, depression will become the world's largest burden disease. The pathogenesis of depression is complex, and it is generally believed that its pathogenesis is related to factors such as genetics, neuroendocr...

Images